Onco-Innovations and Nanosoft Polymers Optimize Polymer Manufacturing Process for ONC010 Nanoparticle Formulation

August 2, 2026

TheNewswire Canada

Overview

Onco-Innovations and Nanosoft Polymers report progress in developing a consistent and scalable polymer manufacturing process for ONC010’s nanoparticle formulation. Their work focuses on optimizing catalyst selection and reaction parameters to improve the polymer’s polydispersity index (PDI) for more uniform molecular weight, which is critical for consistent nanoparticle formation and drug product quality. This aims to establish a robust manufacturing process for Onco’s proprietary PEO-PBCL block copolymer for clinical development.

In Depth

Key Findings

Onco-Innovations and Nanosoft Polymers have collaboratively reported significant progress in developing a consistent and scalable polymer manufacturing process for the nanoparticle formulation of their anti-cancer drug candidate, ONC010. This advancement aims to improve the polymer’s polydispersity index (PDI), achieving a more uniform molecular weight distribution, which is crucial for consistent nanoparticle formation and ultimately for the quality of the drug product.

Technical / Clinical Details

The nanoparticle formulation of ONC010 is based on Onco-Innovations’ proprietary PEO-PBCL (polyethylene oxide-polycaprolactone) block copolymer. The PDI of a block copolymer is a critical indicator of the molecular weight uniformity of individual polymer chains; a lower PDI signifies a narrower molecular weight distribution and more homogeneous polymer chains. For nanoparticle formation, this polymer chain uniformity directly influences the nanoparticles’ size, shape, stability, and drug release characteristics. The current process optimization focuses on precise control of catalyst selection and reaction parameters, including temperature, time, and concentration, to achieve target PDI values. This ensures enhanced batch-to-batch consistency and establishes a reliable supply of high-quality polymer essential for clinical development.

Background & Context

Nanoparticle delivery systems hold immense promise in cancer treatment due to their potential to selectively deliver drugs to tumor sites, reduce side effects, and enhance therapeutic efficacy. However, a major challenge for clinical application has been ensuring the consistency and scalability of complex polymer synthesis and nanoparticle manufacturing processes. Robust manufacturing processes are indispensable to meet the stringent quality standards and regulatory requirements demanded in medical applications. The collaboration between Onco-Innovations and Nanosoft Polymers marks a critical step towards overcoming this challenge and bringing innovative cancer therapies to patients.

Strategic Significance & Outlook

This progress is expected to enable Onco-Innovations to further scale up the manufacturing of its PEO-PBCL block copolymer, thereby accelerating the clinical development of ONC010. A well-established, consistent manufacturing process will facilitate a smoother transition to future commercial production and potentially improve cost efficiency. This technology is applicable not only to ONC010 but also to the development of other nanoparticle-based therapeutics, holding the potential to contribute to the evolution of drug delivery systems overall. Future attention will be on how the pharmacokinetic and pharmacodynamic properties of this polymer are validated in clinical trials.

Source: https://www.thenewswire.com/press-releases/1A0vFwoqw-onco-innovations-reports-progress-toward-a-consistent-and-scalable-polymer-manufacturing-process-supporting-onc010.html

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.